Navigation Links
BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
Date:7/30/2009

BIRMINGHAM, Ala., July 30 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter and six months ended June 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir in the U.S.

"Our efforts at BioCryst remain focused on moving our leading peramivir and forodesine clinical development programs forward," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst Pharmaceuticals. "BioCryst continues to work diligently with government agencies to provide i.v. peramivir as a potential treatment option for an influenza emergency, as well as working to complete the U.S. development of peramivir through the traditional regulatory pathway. The successful Phase 3 studies conducted by our partner Shionogi add to the growing body of data characterizing the efficacy and safety of peramivir as a potential treatment for influenza."

Second Quarter Financial Results

For the three months ended June 30, 2009, collaborative and other research and development revenues were $4.8 million compared to $2.7 million for the three months ended June 30, 2008. Revenues related to the Company's contract with the U.S. Department of Health and Human Services (HHS) for the development of peramivir were higher in this year's quarter compared to the prior year period due to a $4.9 million reserve recorded against revenue in 2008 for amounts BioCryst had previously expected to receive from HHS. The increase in peramivir related revenues was offset by a reduction in revenue from the Company's collaborations with Mundipharma, as well as lower amortization of deferred revenue from our collaboration arrangements.

Research and development (R&D) expenses
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
2. BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
3. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
4. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
5. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
6. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
7. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
8. Encision Reports Profitable First Fiscal Quarter Results
9. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
10. Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share
11. BioMed Realty Trust Reports Second Quarter 2009 Operating and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... ... Constitution, the new Lifetime reality series, “Atlanta Plastic” is getting attention for moving ... plastic surgery, with its predominantly African-American cast of doctors and patients. Beverly Hills ...
(Date:8/3/2015)... ... August 03, 2015 , ... They know every second counts. And when ... Center offers some of the best care in the nation. For the past two ... fastest average blood clot removal time in the country. During the months of June ...
(Date:8/3/2015)... ... August 03, 2015 , ... Kantor ... in favor of the firm’s client Rebecca Hamsher, deciding that in accordance with ... reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other mental health ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... Irving, Texas (PRWEB) , ... August 03, 2015 ... ... awarded an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and ... care and reduce health care costs. , Annually, more than 8.6 million ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3
... ― As part of preparations for a possible large-scale ... local levels should determine where and how anthrax-preventing antibiotics ... report from the Institute of Medicine. The report ... with the federal government to assess the benefits and ...
... a promising yet volatile French SME in the medical ... The seven founders teamed-up with Grard Heinrich, an experienced ... Ventures, an investment fund specialising in start-up support. Now ... are backing CrossJect, which is awaiting favourable conditions for ...
... pressure to share sexual images via the new phenomenon of ... found. ,Sexting, is the practice of sending and receiving ... is one of the first academic investigations into ,sexting, from ... to the 2011 Australasian Sexual Health Conference in Canberra. ...
... (HealthDay News) -- Yawning may be a natural way of ... examined the frequency of yawns among 80 people in the ... seasonal variations. Yawning is known to be "contagious," the ... yawning, nearly half of the participants yawned while outdoors in ...
... at least on the healthy part. "Early to bed and early ... youths keep slimmer and more physically active than their night-owl peers, ... A study in the Oct. 1 issue of the journal ... participants, ages 9 to 16, and compared their weights and uses ...
... , THURSDAY, Sept. 29 (HealthDay News) -- Men over ... undertreated for their condition, according to a new study. ... by other health problems -- or "co-morbid" conditions -- are ... as expected, University of California, Los Angeles researchers found. ...
Cached Medicine News:Health News:Community storage of anthrax-preventing antibiotics should be determined by state 2Health News:Community storage of anthrax-preventing antibiotics should be determined by state 3Health News:An innovation star for Europe 2Health News:An innovation star for Europe 3Health News:'Sexting' driven by peer pressure 2Health News:Yawning May Help the Brain Chill Out 2Health News:Early to bed and early to rise -- study suggests it's keeping kids leaner 2Health News:Otherwise Healthy Older Men Undertreated for Prostate Cancer: Study 2Health News:Otherwise Healthy Older Men Undertreated for Prostate Cancer: Study 3
(Date:8/3/2015)... N.J. , Aug. 3, 2015 Ortho ... has been named Chief Corporate Brand and Communications ... firm,s executive leadership team, Bouryal will lead the company,s ... builds on its transition to an independent company by ... report to Chairman and Chief Executive Officer Dr. ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... 2015 Global physiotherapy ... USD 24.7 billion by 2022, according to a ... prevalence of neurological and musculoskeletal disorders are expected ... forecast period. The presence of efficient and effective ... the technologies coupled with implementation of favorable government ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
... Light transmitted via fiber optic ... Keeler otoscopes have bright halogen ... visualization of aural canal. ... capability. Ring rheostat for ...
Durable, simple and easy to use. Lightweight, base can detach and be used as a penlight....
Pocket-sized instrument. All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheos...
Medicine Products: